# Viking Therapeutics Data Boosts Hope but Cash Burn Lingers

> Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate.
- Title: Viking Therapeutics Data Boosts Hope but Cash Burn Lingers
- Summary: Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate. VK2735 maintains 97% weight loss with…
- Keywords: viking therapeutics, vk2735, obesity drug, phase 3 trial, cash burn, glp-1/gip, maintenance dosing, viking therapeutics vktx, Viking, Therapeutics, Data, Boosts
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/viking-therapeutics-vktx-vk2735-data-look-strong-but-cash-burn-still-matters
- Author: Newsdesk
- Published: 2026-09-28T12:41:09+00:00
- Read time: 1 min
- Topics: viking therapeutics, vk2735, obesity drug, phase 3 trial, cash burn, glp-1/gip, maintenance dosing, viking therapeutics vktx
## VK2735 Maintenance Data
Patients maintaining up to 97% of weight loss after induction with every-other-week dosing.

> Patients who switched to every-other-week maintenance dosing maintained up to 97% of body-weight reduction achieved during induction.
## Q2 2026 Financials
Reported $128.1 million net loss versus $65.6 million in Q2 2025 with rising R&D spending.
## Cash Position
Cash and short-term investments at $501.7 million as of June 30, 2026, down from $706 million in December 2025.
## VANQUISH Trial Progress
VANQUISH-1 enrolled over 4,500 patients and VANQUISH-2 over 1,000 patients ahead of schedule.
## Oral Formulation Plan
Planned Phase 3 oral VK2735 study beginning in Q4 2026 to improve patient access.
## Investor Watchpoints
Phase 3 enrollment, oral formulation results, and cash runway critical for next steps.
## Key takeaway

VK2735 maintains 97% weight loss with every-other-week dosing after induction.